source
- UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapyIn briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor's assertion that a Phase 3 trial met its primary outcome measures.
- InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testInnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.